Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.

Status: Recruiting
Location: See all (9) locations...
Study Type: Observational
SUMMARY

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or

• GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or

• GOLD 3 and 4 (FEV1 \<50%).

Locations
Other Locations
Brazil
Research Site
RECRUITING
Bahia
Research Site
NOT_YET_RECRUITING
Belém
Research Site
NOT_YET_RECRUITING
Brasília
Research Site
NOT_YET_RECRUITING
Campo Grande
Research Site
NOT_YET_RECRUITING
Florianópolis
Research Site
RECRUITING
Santo André
Research Site
NOT_YET_RECRUITING
São Paulo
Research Site
RECRUITING
São Paulo
Research Site
NOT_YET_RECRUITING
Uberlândia
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-01-31
Estimated Completion Date: 2027-02-26
Participants
Target number of participants: 693
Sponsors
Leads: AstraZeneca

This content was sourced from clinicaltrials.gov